RA
MACK

Rise Advisors’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Rise Advisors’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-272
Closed – – 1246
2024
Q3 		$0 Hold
272
– – ﹤0.01% 1261
2024
Q2 		$4.11K Hold
272
– – ﹤0.01% 1089
2024
Q1 		$4.01K Hold
272
– – ﹤0.01% 1102
2023
Q4 		$3.64K Hold
272
– – ﹤0.01% 412
2023
Q3 		$3.35K Hold
272
– – ﹤0.01% 411
2023
Q2 		$3.34K Hold
272
– – ﹤0.01% 454
2023
Q1 		$3.34K Hold
272
– – ﹤0.01% 505
2022
Q4 		$3.11K Hold
272
– – ﹤0.01% 506
2022
Q3 		$1K Hold
272
– – ﹤0.01% 696
2022
Q2 		$2K Hold
272
– – ﹤0.01% 599
2022
Q1 		$2K Hold
272
– – ﹤0.01% 575
2021
Q4 		$1.06K Buy
+272
New +$1.18K ﹤0.01% 598

Other funds holding MACK

MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return

Rise Advisors's MACK Position: Q4 2024 in Review

Rise Advisors sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2024, closing a stake of 272 shares.

Rise Advisors first reported a position in MACK in Q4 2021 and held it in 12 quarters. The position peaked at $4.11K in Q2 2024. 2 funds tracked by Wall St. Rank hold MACK as of Q4 2024.

  • Rise Advisors reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • Rise Advisors sold 272 Merrimack Pharmaceuticals, Inc. shares in Q4 2024.
  • Rise Advisors first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2021 and held it in 12 quarters.
  • Rise Advisors's Merrimack Pharmaceuticals, Inc. position peaked at $4.11K in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2024.

Based on Rise Advisors's 13F filing for Q4 2024, filed 7 Jan 2025.